Humana Stock Sinks on Weak Medicare Star Ratings: What to Know
Humana stock is spiraling Wednesday after the CMS provided preliminary Star Ratings data for the insurer's 2025 Medicare Advantage plans.


Humana (HUM) stock is plunging in Wednesday's session after the health benefits company announced preliminary 2025 Medicare Advantage (MA) Star Ratings data provided by the Centers for Medicare and Medicaid Services (CMS).
HUM is down 15% at last check, making it the worst S&P 500 stock so far today. And this follows a 12% decline in the stock yesterday when the CMS plan finder website included Star Ratings for 2025 plans.
In a filing with the Securities and Exchange Commission (SEC) this morning, Humana said that approximately 1.6 million, or 25%, of its members are currently enrolled in MA plans that are rated as four stars and above for 2025, which is down from 94% in 2024.

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"The decline in Stars performance for 2025 will impact Humana's quality bonus payments in 2026," Humana said in the filing. "2025 Star rating details are expected to be formally released by CMS on or around October 10th."
However, Humana went on to say that it believes "there may be potential errors" in the calculations by the CMS. It currently has outstanding appeals and said it has requested additional information to ensure the accuracy of the ratings.
"Despite ongoing appeal efforts, the Company is disappointed with its performance and has initiatives underway focused on improving its operating discipline and returning to an industry leading Stars position as quickly as possible," Humana said, adding that it "is exploring all available options to mitigate the expected 2026 revenue headwind related to its 2025 Star ratings in the event its challenges to the results are unsuccessful."
Is Humana stock a buy, sell or hold?
Humana has woefully underperformed the broader market so far this year, down 38% on a total return basis (price change plus dividends) vs the S&P 500's 21% gain. Yet, Wall Street remains bullish on the healthcare stock.
According to S&P Global Market Intelligence, the average analyst target price for HUM stock is $384.28, representing implied upside of more than 60% to current levels. Additionally, the consensus recommendation is Buy. However, these ratings and price targets may very well change following the news.
Financial services firm Argus Research has already moved to the sidelines when it comes to the large-cap stock, as evidenced by its Hold rating.
"Humana faces headwinds to revenue and earnings growth, as its profit margin is squeezed by an increase in medical utilization," wrote Argus Research analysts David Toung and Owen Shelley in an August 13 note. "Despite the favorable demographics of an aging population, with some 26 million Americans aging into Medicare-eligibility from 2023 through 2030, we are concerned that Medicare Advantage is not an unalloyed growth vehicle."
Related Content
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Joey Solitro is a freelance financial journalist at Kiplinger with more than a decade of experience. A longtime equity analyst, Joey has covered a range of industries for media outlets including The Motley Fool, Seeking Alpha, Market Realist, and TipRanks. Joey holds a bachelor's degree in business administration.
-
Can the 'Guardrails Approach' Protect Your Retirement Investments?
This investing method helps retirees avoid running out of money, even in a highly volatile market.
By Simon Constable
-
Social Security Is Taxable, But There Are Workarounds
If you're strategic about your retirement account withdrawals, you can potentially minimize the taxes you'll pay on your Social Security benefits.
By Todd Talbot, CFP®, NSSA, CTS™
-
Social Security Is Taxable, But There Are Workarounds
If you're strategic about your retirement account withdrawals, you can potentially minimize the taxes you'll pay on your Social Security benefits.
By Todd Talbot, CFP®, NSSA, CTS™
-
Serious Medical Diagnosis? Four Financial Steps to Take
A serious medical diagnosis calls for updates of your financial, health care and estate plans as well as open conversations with those who'll fulfill your wishes.
By Thomas C. West, CLU®, ChFC®, AIF®
-
What Wall Street's CEOs Are Saying About Trump's Tariffs
We're in the thick of earnings season and corporate America has plenty to say about the Trump administration's trade policy.
By Karee Venema
-
To Stay on Track for Retirement, Consider Doing This
Writing down your retirement and income plan in an investment policy statement can help you resist letting a bear market upend your retirement.
By Matt Green, Investment Adviser Representative
-
How to Make Changing Interest Rates Work for Your Retirement
Higher (or lower) rates can be painful in some ways and helpful in others. The key is being prepared to take advantage of the situation.
By Phil Cooper
-
When to Sell Your Stock
Knowing when to sell a stock is a major decision investors must make. While there's no one correct answer, we look at some best practices here.
By Charles Lewis Sizemore, CFA
-
Within Five Years of Retirement? Five Things to Do Now
If you're retiring in the next five years, your to-do list should contain some financial planning and, according to current retirees, a few life goals, too.
By Evan T. Beach, CFP®, AWMA®
-
The Home Stretch: Seven Essential Steps for Pre-Retirees
The decade before retirement is the home stretch in the race to quit work — but there are crucial financial decisions to make before you reach the finish line.
By Mike Dullaghan, AIF®